AbbVie has unveiled new data showing high and durable undetectable minimal residual disease rates in patients with chronic lymphocytic leukaemia treated with venetoclax in combination with rituximab.Original Article
You may also like
Nouscom to present re‑treatment data in Lynch...
ViiV Healthcare to unveil new HIV treatment data at...
Almirall’s paediatric registration of Ebglyss for...
The Bloc appoints Jon Chapman as European Executive...
Early Genomic Indicators of Praziquantel Resistance in...
Flu Virus Interaction with Host Cell Machinery Mapped...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.